151 related articles for article (PubMed ID: 10701306)
21. Omapatrilat: still a promise in salt-sensitive hypertension?
Tojo A; Fujita T; Wilcox CS
J Hypertens; 2003 Jan; 21(1):31-2. PubMed ID: 12544430
[No Abstract] [Full Text] [Related]
22. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
[TBL] [Abstract][Full Text] [Related]
23. [Heart failure and vasopeptidase inhibitors].
Bareiss P; Ohlmann P; Roul G
Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
[TBL] [Abstract][Full Text] [Related]
24. Emerging treatments for hypertension: potential role for vasopeptidase inhibition.
Weber M
Am J Hypertens; 1999 Nov; 12(11 Pt 2):139S-147S. PubMed ID: 10596765
[TBL] [Abstract][Full Text] [Related]
25. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
26. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
Trindade PT; Rouleau JL
Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
[TBL] [Abstract][Full Text] [Related]
27. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
McClean DR; Ikram H; Mehta S; Heywood JT; Rousseau MF; Niederman AL; Sequeira RF; Fleck E; Singh SN; Coutu B; Hanrath P; Komajda M; Bryson CC; Qian C; Hanyok JJ;
J Am Coll Cardiol; 2002 Jun; 39(12):2034-41. PubMed ID: 12084605
[TBL] [Abstract][Full Text] [Related]
28. Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Klapholz M; Thomas I; Eng C; Iteld BJ; Ponce GA; Niederman AL; Bilsker M; Heywood JT; Synhorst D
Am J Cardiol; 2001 Sep; 88(6):657-61. PubMed ID: 11564390
[TBL] [Abstract][Full Text] [Related]
29. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Lüscher TF
Hypertension; 2001 Apr; 37(4):1108-13. PubMed ID: 11304511
[TBL] [Abstract][Full Text] [Related]
30. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157
[No Abstract] [Full Text] [Related]
31. Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition.
Mitchell GF; Lacourcière Y; Arnold JM; Dunlap ME; Conlin PR; Izzo JL
Hypertension; 2005 Nov; 46(5):1111-7. PubMed ID: 16230523
[TBL] [Abstract][Full Text] [Related]
32. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
Machowska A; Juszczak K; Novak P; Thor P
Folia Med Cracov; 2009; 50(3-4):35-42. PubMed ID: 21853869
[TBL] [Abstract][Full Text] [Related]
33. Vasopeptidase inhibition and angio-oedema.
Messerli FH; Nussberger J
Lancet; 2000 Aug; 356(9230):608-9. PubMed ID: 10968427
[No Abstract] [Full Text] [Related]
34. Vasopeptidase inhibition: a new direction in cardiovascular treatment.
Asher JR; Naftilan AJ
Curr Hypertens Rep; 2000 Aug; 2(4):384-91. PubMed ID: 10981174
[TBL] [Abstract][Full Text] [Related]
35. Omapatrilat may indeed not be much superior (OMINOUS).
Cheng TO
Int J Cardiol; 2003 Sep; 91(1):113. PubMed ID: 12957741
[No Abstract] [Full Text] [Related]
36. Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction.
Holzgrefe HH; Arthur SR; Powell JR
Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):696-703. PubMed ID: 12100002
[TBL] [Abstract][Full Text] [Related]
37. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
Levy Z; Dvir A; Shaish A; Trestman S; Cohen H; Levkovietz H; Rhachmani R; Ravid M; Harats D
Int J Exp Diabesity Res; 2003; 4(1):59-64. PubMed ID: 12745671
[TBL] [Abstract][Full Text] [Related]
38. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
Eisenstein EL; Nelson CL; Simon TA; Smitten AL; Lapuerta P; Mark DB
Am Heart J; 2002 Jun; 143(6):1112-7. PubMed ID: 12075271
[TBL] [Abstract][Full Text] [Related]
39. Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.
Iyer RA; Mitroka J; Malhotra B; Bonacorsi S; Waller SC; Rinehart JK; Roongta VA; Kripalani K
Drug Metab Dispos; 2001 Jan; 29(1):60-9. PubMed ID: 11124231
[TBL] [Abstract][Full Text] [Related]
40. Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure.
Witte K; Thackray S; Banerjee T; Clark AL; Cleland JG
Eur J Heart Fail; 2000 Mar; 2(1):107-12. PubMed ID: 10742710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
